News - Synairgen

Press Releases

News

13th January 2021

First Patient Dosing in Phase III SG018 Trial

18th December 2020

COVID-19 Clinical Programme Update

13th November 2020

Lancet Respiratory Medicine publishes Phase 2 data

2nd November 2020

Result of General Meeting and Total Voting Rights

2nd November 2020

Result of Open Offer

15th October 2020

Results of Placing

14th October 2020

Placing and Open Offer

2nd October 2020

Appointment of Joint Broker

29th September 2020

Interim results for the six months ended 30 June 2020

29th September 2020

Synairgen and Clinigen sign Managed Access Program agreement with SNG001 for treatment of hospitalised patients with COVID-19

9th September 2020

Synairgen IP Update

8th September 2020

Positive interim analysis of SNG001 in COPD

21st July 2020

Clarification Regarding COVID-19 Trial

20th July 2020

Positive results from trial of SNG001 in hospitalised COVID-19 patients

29th June 2020

Result of AGM

18th June 2020

National expansion of home-based COVID-19 trial

3rd June 2020

Posting of Annual Report and Notice of AGM

28th May 2020

Recruitment of Hospitalised Patients in COVID-19 Trial Completed

26th May 2020

Initiation of SNG001 in home setting

26th May 2020

Preliminary statement of results for the year ended 31 December 2019

30th April 2020

Approval received to extend SG016 study of SNG001 in COVID-19 to initiate patients in the home environment

14th April 2020

Result of General Meeting

31st March 2020

Commencement of dosing in COVID-19 trial

26th March 2020

Result of fundraising

25th March 2020

Proposed fundraising

18th March 2020

Synairgen to start trial of SNG001 in COVID-19 imminently

30 September 2019

Interim results for the six months ended 30 June 2019

27 September 2019

Phase II Biomarker Data for SNG001 to be presented at European Respiratory Society

24th July 2019

Phase II Clinical Trial Update in Patients with COPD

3rd June 2019

Result of AGM

18th April 2019

Directorate Change, Posting of Annual Report, and Notice of AGM

14th March 2019

Positive DSMC Review of Phase II Study for SNG001

25th February 2019

Preliminary statement of results for the year ended 31 December 2018

17th January 2019

Update on LOXL2 programme with Pharmaxis

22nd October 2018

Synairgen commences dosing in part 2 of its Phase II clinical trial in patients with COPD

12th October 2018

Result of General Meeting

25th September 2018

Result of Fundraise

25th September 2018

Proposed Fundraise to raise c.£2.9 million

25th September 2018

Interim results for the six months ended 30 June 2018

28th June 2018

Positive SNG001 Biomarker Data in COPD Patients

22nd June 2018

Result of Synairgen AGM

22nd June 2018

Synairgen Safety Data with SNG001 in COPD Patients

17th May 2018

Posting of Annual Report and Notice of AGM

15th March 2018

Preliminary statement of results for the year ended 31 December 2017

7th February 2018

Synairgen starts dosing in phase II COPD study

27th December 2017

Data update from clinical trial of inhaled interferon beta (SNG001) and clinical plan for COPD

14th December 2017

Update on LOXL2 Programme and Collaboration with Pharmaxis

27th September 2017

Interim results for the six months ended 30 June 2017

6th September 2017

LOXL2 Inhibitor Update

28th June 2017

Result of 2017 Annual General Meeting

5th June 2017

Posting of Annual Report and Notice of AGM

17th May 2017

Preliminary statement of results for the year ended 31 December 2016

27th April 2017

AZD9412 Update

10th March 2017

Additional Positive Data in Lung Fibrosis

12th October 2016

AZD9412 Clinical Trial Update

22nd September 2016

Interim results for the six months ended 30 June 2016

8th September 2016

Notice of Interim Results

14th June 2016

Results of 2016 Annual General Meeting

17th May 2016

Posting of Annual Report and Notice of AGM

22nd March 2016

Preliminary statement of results for the year ended 31 December 2015

22nd March 2016

Positive LOXL2 results

3rd March 2016

Notice of Preliminary Results

16th September 2015

Interim results for the six months ended 30 June 2015

21st August 2015

Notice of Interim Results

5th August 2015

Research collaboration with Pharmaxis in IPF

2nd July 2015

AstraZeneca commences AZD9412 Phase II trial in severe asthma

22nd June 2015

Results of 2015 Annual General Meeting

15th May 2015

Notice of Annual General Meeting

22nd April 2015

Posting of Annual Report and Accounts

3rd March 2015

Preliminary statement of results for the year ended 31 December 2014

25th September 2014

Interim results for the six months ended 30 June 2014

17th September 2014

Notice of Interim Results

4th July 2014

Placing

12th June 2014

AstraZeneca Licence Deal

9th June 2014

Result of General Meeting

16th May 2014

Notice of Annual General Meeting

9th May 2014

Notice of Report and Accounts

20th March 2014

Preliminary statement of results for the year ended 31 December 2013

5th March 2014

Licensing update, placing to raise £1.5m and notice of results

12th August 2013

Interim results for the six months ended 30 June 2013

18th July 2013

Positive Anti-Inflammatory and Anti-Viral Data

10th June 2013

Result of Annual General Meeting

9th May 2013

Notice of Annual General Meeting

9th April 2013

Notice of Report and Accounts

13th February 2013

Preliminary statement of results for the year ended 31 December 2012

5th December 2012

Trading Update

30th October 2012

Director’s dealing

10th August 2012

Interim results for the six months ended 30 June 2012

18th July 2012

Placing

25th June 2012

Result of General Meeting

1 2 3 … 6 »

Synairgen plc
Registered in England and Wales No. 5233429

Registered office
Mailpoint 810, Level F, South Block,
Southampton General Hospital,
Tremona Road,
Southampton, SO16 6YD, UK

Press Releases

Investors